Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of agomelatine on cerebral activity during emotional processing in major depressive disorder
2007-005564-27Phase 2Completed
- Sponsor
- Servier
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Agomelatine 25 mg with Placebo (double-blind), then agomelatine open-label (2 arms). Primary endpoint: Cerebral activation measured by fMRI during emotional stimulus processing. Started Mar 2008; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2007-005564-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005564-27.